Failed IBD trial dents confidence in BMS' deucravacitinib

Bristol-Myers Squibb's hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) have been hit by a mid-stage failure in ulce

Holistic immunology: Supporting patients at every stage of t...

As part of our series from leaders at Janssen, the company’s Max Pahlow looks at how approaches

Despite biosims, ulcerative colitis drugs still cost too muc...

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough to be cost-effective, says the Institute for Clinical and Economic Review

Roche’s ulcerative colitis drug etrolizumab looks shaky afte...

Roche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans firmly towards the latter.

J&J gets Stelara okay in Europe for ulcerative colitis

Allergan says it will shed two drugs as AbbVie takeover loom...